Curated News
By: NewsRamp Editorial Staff
November 09, 2026
Oral GLP-1 Orforglipron Cuts Sleep Apnea Events by 18 per Hour
TLDR
- Eli Lilly's orforglipron cut sleep apnea events by 18 per hour, offering a first oral GLP-1 edge over placebo and CPAP limitations.
- Two year-long ATTAIN-OSA trials randomized 712 adults to daily oral orforglipron or placebo, measuring sleep interruptions via overnight studies at baseline and week 52.
- A daily pill could expand sleep apnea treatment access, improving sleep, blood pressure, and quality of life for those unable to use CPAP.
- Orforglipron reduced breathing interruptions by about 18 per hour versus 5 with placebo, also lowering weight and inflammation markers.
Impact - Why it Matters
This news matters because obstructive sleep apnea affects an estimated 1 billion adults globally and is closely linked to high blood pressure, heart disease, and stroke. Current treatments like CPAP machines are effective but often poorly tolerated, leaving many patients untreated. An oral GLP-1 pill that not only reduces breathing interruptions but also lowers blood pressure, inflammation, and body weight could transform sleep apnea management. By addressing both sleep apnea severity and cardiovascular risk factors, orforglipron may offer a convenient, accessible option that improves quality of life and long-term heart health for millions. If approved, it could be used alongside CPAP or as an alternative for those who cannot use CPAP, expanding treatment options and potentially reducing the burden of cardiovascular disease associated with sleep apnea.
Summary
New late-breaking research presented at the American Heart Association’s Scientific Sessions 2026 reveals that the daily oral GLP-1 medication orforglipron significantly reduces breathing interruptions in adults with moderate-to-severe sleep apnea and excess weight. In two year-long ATTAIN-OSA trials involving 712 participants, those taking orforglipron experienced about 18 fewer breathing interruptions per hour of sleep after 52 weeks, compared with about 5 fewer in the placebo group. The studies, funded by Eli Lilly and Company and simultaneously published in JAMA, also showed meaningful improvements in cardiovascular risk factors: participants on orforglipron lost 10-11% of body weight versus 1-2% with placebo, saw greater reductions in high-sensitivity C-reactive protein (hs-CRP), and had systolic blood pressure drops of about 7 points compared to 2 points with placebo.
“If approved to treat obstructive sleep apnea, orforglipron could be a promising oral pharmacologic option for people with overweight or obesity and this condition,” said presenting author Vaishnavi Kundel, M.D., M.Sc., of the Icahn School of Medicine at Mount Sinai. The trials included both CPAP users and non-users, with broadly similar results, suggesting the pill could complement or offer an alternative for those who cannot tolerate CPAP. Side effects were mostly mild to moderate, including nausea, diarrhea, and constipation.
Kundel emphasized the cardiovascular implications: “Untreated moderate to severe sleep apnea frequently goes hand in hand with high blood pressure, which can strain the heart and blood vessels over time, leading to increased risk of heart disease and stroke.” The findings are considered preliminary until full peer review, but they highlight a potential new oral treatment for a condition affecting an estimated 1 billion adults worldwide.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Oral GLP-1 Orforglipron Cuts Sleep Apnea Events by 18 per Hour
